Human computer interaction with a PIM application: Merging activity, location and social setting into context

This is the post-print version of the Article. The official published version can be accessed from the link below - Copyright @ 2009 Springer VerlagPersonal Information Managers exploit the ubiquitous paradigm in mobile computing technology to integrate services and programs for business and leisure. Recognizing that every situation is constituted by information and events, this context will vary depending on the situation users are in, and the tasks they are about to commit. The value of context as a source of information is highly recognized and for individual dimensions context has been both conceptually described and prototypes implemented. The novelty in this paper is a new implementation of context by integrating three dimensions of context: social information, activity information and geographical position. Based on an application developed for Microsoft Window Mobile these three dimensions of context are explored and implemented in an application for mobile telephone users. Experiment conducted show the viability of tailoring contextual information in three dimensions to provide user with timely and relevant information

Predictors of normal and abnormal outcome in clinical brain dopamine transporter imaging

Brain dopamine transporter (DAT) imaging with [123I]FP-CIT SPECT can be used to evaluate the integrity of the mesostriatal dopaminergic system in patients with clinically uncertain parkinsonism. To evaluate whether scanning a patient is clinically necessary, it is vital to understand possible factors that affect the scanning result. Therefore, we investigated an unselected sample of 538 consecutively scanned patients from a 6-year period, and the demographic data and indications for DAT SPECT were recorded. After scanning, the patients were divided into groups according to the scanning outcome. Multivariate binary logistic regression analyses were performed to investigate whether the pre-imaging variables had independent associations with the outcome of the scan. Three hundred and three (56.3 %) patients had abnormal scans showing a dopaminergic deficit. The independent factors associated with abnormal scans were older age (p = 0.002), asymmetry of motor symptoms (p = 0.005) and shorter symptom duration (p p = 0.004), whereas the possibility of medication-induced parkinsonism was associated with a higher probability of a normal scan (35.4 %, p = 0.036). The probability of an abnormal outcome in clinical brain DAT imaging increases with known risk factors of neurodegenerative parkinsonism. However, a long duration of uncertain motor symptoms and suspicion of medication-induced parkinsonism are associated with a higher probability of a normal outcome. The findings reflect epidemiological factors in parkinsonism together with referral biases that may be used to improve the clinical use of DAT imaging.</p

Prognostic utility of human complement factor H related protein test (the BTA stat® Test)

The purpose of the study was to determine, in addition to well-known prognostic factors, histological grade, stage, tumour size and multiplicity, the correlation of BTA stat Test on disease free interval (DFI) on primary superficial bladder cancer. A total of 116 patients with newly diagnosed bladder cancer were evaluated in a prospective multicentre study. A voided urine sample was obtained prior to TURB and split for culture, cytology and BTA stat testing. Follow-up data for the patients were collected until the first recurrence or the last visit and the DFI was analysed by Kaplan–Meier method and Cox analysis. Ninety-seven of the 116 (83.6%) patients were eligible for analysis. The BTA stat Test was positive in 73 (75.3%) patients, whereas cytology detected 20 (20.6%) cases. The DFI was found to be shorter among patients with a positive BTA stat Test, and also among those with intermediate or high-grade tumours. The BTA stat Test result divided patients with grade 2 tumours into two prognostic groups, in that those testing positive had 68.6% risk of recurrence during the first year compared to 42.9% risk of those with a negative test result (P = 0.041). Although the effect of tumour size on DFI was notable, the difference did not reach statistical significance (P = 0.064). Number of tumours was not related to DFI, nor was the difference between different stage of tumour of significance. BTA stat Test is not only sensitive in detection of primary bladder cancer, but also might have some independent prognostic significance. © 2001 Cancer Research Campaign http://www.bjcancer.co

Ventral striatal dopaminergic defect is associated with hallucinations in Parkinson's disease

ConclusionsLow striatal DAT function may predispose PD patients to VHs, and the regional distribution of the findings suggests a particular role of the ventral striatum. This is in line with non-PD research that has implicated ventral striatal dysfunction in psychosis.</p

Survival in Parkinson's disease in relation to striatal dopamine transporter binding

Objective: To investigate whether dopamine transporter (DAT) binding, as measured with single photon emission computed tomography (SPECT), can be used to predict mortality in patients with Parkinson's disease (PD). Methods: A total of 162 patients with PD and abnormal [I-123]FP-CIT SPECT were clinically followed for a median of 5.8 years. A multivariate Cox regression model was used to investigate survival with the independent predictors of age, gender, severity of motor impairment, levodopa-equivalent daily dose of medication, presence of cognitive defects, and putaminal specific binding ratio (SBR) of [I-123]FP-CIT. In addition, associations between striatal and extrastriatal SBRs and survival were investigated using voxel-based analyses.Results: The overall mortality was 25.9%, and the Kaplan-Meier estimate for mortality was 36%. Older age (P< 0.001), presence of cognitive defects (P = 0.001), and more severe motor symptom severity (P = 0.002) were significantly associated with increased mortality. No associations were found between putaminal DAT binding and survival (P = 0.99). There were no significant differences in SBRs in any striatal or extrastriatal region between survivors and non-survivors, and no associations were found between SBRs and scan-to-death intervals among non-survivors.Conclusions: Unlike the severity of motor and cognitive symptoms, the level of striatal dopaminergic defect in DAT SPECT does not predict mortality in PD. Although presynaptic dopaminergic functional imaging may have value as a diagnostic tool, the clinical symptom-based characteristics are superior for predicting lifespan. (c) 2017 Elsevier Ltd. All rights reserved

Visual versus automated analysis of [I-123]FP-CIT SPECT scans in parkinsonism

The clinical evaluation of dopamine transporter (DAT) SPECT scans typically relies on visual analysis in combination with an automated semi-quantitative method. The interpretation of the results may be difficult in cases that show disagreement between the two methods on the borderline of abnormality. The frequency and clinical characteristics of such cases are unclear. Automated semi-quantitative analyses and independent visual analyses by two experienced nuclear medicine physicians and four inexperienced raters were performed for 120 patients with clinically uncertain parkinsonism scanned with brain [I-123]FP-CIT SPECT. Agreement was evaluated with kappa statistics. The clinical characteristics of patients who had discrepant findings between the two analysis methods were investigated. The expert raters outperformed nonexperts in terms of agreement between visual and automated analyses (kappa = 0.66, 0.72 vs. 0.23-0.54) and between raters (kappa = 0.81 vs. 0.44-0.63). Twelve patients showed discrepant findings between the visual and automated analyses. These patients were older compared to other patients (p = 0.023), had 17.6 % lower mean striatal tracer binding compared to normal scans (p = 0.003) and 62.7 % higher compared to abnormal scans (p < 0.001). After a minimum of 4.5 years of clinical follow-up, none of these patients developed neurodegenerative parkinsonism. Clinical DAT SPECT scans show discrepancies between visual and automated analyses in 10 % of cases. The patients with discrepant findings are older, show normal to slightly abnormal tracer binding, and importantly, do not develop neurodegenerative parkinsonism syndromes. Visual analyses by experienced raters are reliable, but the diagnostic accuracy in discrepant cases can be improved by an automated method

Obscuration beyond the nucleus: infrared quasars can be buried in extreme compact starbursts

In the standard quasar model, the accretion disk obscuration is due to the canonical dusty torus. Here, we argue that a substantial part of the quasar obscuration can come from the interstellar medium (ISM) when the quasars are embedded in compact starbursts. We use an obscuration-unbiased sample of 578 infrared (IR) quasars at $z\approx 1-3$ and archival ALMA submillimeter host galaxy sizes to investigate the ISM contribution to the quasar obscuration. We calculate SFR and ISM column densities for the IR quasars and a control sample of submillimeter galaxies (SMGs) not hosting quasar activity and show that: (1) the quasar obscured fraction is constant up to $\rm SFR\approx 300 \: M_{\odot} \: yr^{-1}$, and then increases towards higher SFR, suggesting that the ISM obscuration plays a significant role in starburst host galaxies, and (2) at $\rm SFR\gtrsim 300 \: M_{\odot} \: yr^{-1}$, the SMGs and IR quasars have similarly compact submillimeter sizes ($R_{\rm e}\approx 0.5-3\rm \: kpc$) and, consequently, the ISM can heavily obscure the quasar, even reaching Compton-thick ($N_{\rm H}>10^{24} \rm \: cm^{-2}$) levels in extreme cases. Based on our results, we infer that $\approx 10-30\%$ of the IR quasars with $\rm SFR\gtrsim 300 \: M_{\odot} \: yr^{-1}$ are obscured solely by the ISM.Comment: Accepted for publication in MNRAS Letter

Molecular Gas Reservoirs of z ∼ 2 Galaxies: A Comparison of CO(1−0) and Dust-based Molecular Gas Masses

We test the use of long-wavelength dust continuum emission as a molecular gas tracer at high redshift, via a unique sample of a dozen z ~ 2 galaxies with observations of both the dust continuum and CO(1−0) line emission (obtained with the Atacama Large Millimeter Array and Karl G. Jansky Very Large Array, respectively). Our work is motivated by recent high-redshift studies that measure molecular gas masses (M_(mol)) via a calibration of the rest-frame 850 μm luminosity (L_(850 μm,rest)) against the CO(1−0)-derived M_(mol) of star-forming galaxies. We therefore test whether this method is valid for the types of high-redshift, star-forming galaxies to which it has been applied. We recover a clear correlation between the rest-frame 850 μm luminosity, inferred from the single-band, long-wavelength flux, and the CO(1−0) line luminosity, consistent with the samples used to perform the 850 μm calibration. The molecular gas masses, derived from L_(850 μm,rest), agree to within a factor of two with those derived from CO(1−0). We show that this factor of two uncertainty can arise from the values of the dust emissivity index and temperature that need to be assumed in order to extrapolate from the observed frequency to the rest-frame at 850 μm. The extrapolation to 850 μm therefore has a smaller effect on the accuracy of M_(mol) derived via single-band dust-continuum observations than the assumed CO(1−0)-to- M_(mol) conversion factor. We therefore conclude that single-band observations of long-wavelength dust emission can be used to reliably constrain the molecular gas masses of massive, star-forming galaxies at z ≳ 2

Symptoms and diagnostic delays in bladder cancer with high risk of recurrence: results from a prospective FinnBladder 9 trial

Purpose: To investigate the symptoms and delays in the clinical pathway of bladder cancer (BC).Methods: This is a substudy of a prospective, randomized, multicenter phase III study (FinnBladder 9, NCT01675219) where the efficacy of photodynamic diagnosis and 6 weekly optimized mitomycin C instillations are studied in pTa bladder cancer with high risk for recurrence. The data of presenting symptoms and critical time points were prospectively collected, and the effect of factors on delays was analyzed.Results: At the time of analysis, 245 patients were randomized. Analysis included 131 patients with primary bladder cancer and their complete data. Sixty-nine percent had smoking history and 67% presented with macroscopic hematuria. Median patient delay (from symptoms to health-care contact) was 7 days. The median general practice delay (from health-care contact to urology referral) was 8 days. Median time from urology referral to cystoscopy was 23 days and from cystoscopy to TUR-BT 21 days. Total time used in the clinical pathway (from symptom to TUR-BT) was 78 days. Current and former smokers had non-significantly shorter patient-related and general practice delays compared to never smokers. TUR-BT delay was significantly shorter in patients with malignant cytology (16 days) compared to patients with benign cytology (21 days, p = 0.03).Conclusions: Patient-derived delay was short and most of the delay occurred in the referral centers. The majority had macroscopic hematuria as the initial symptom. Surprisingly, current and past smokers were more prone to contact the health-care system compared to never smokers.</p